The longitudinal cerebrospinal fluid metabolomic profile of amyotrophic lateral sclerosis

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Volumn 16, Issue 7-8, 2015, Pages 456-463

  Gray, Elizabeth ^a   Larkin, James R ^a   Claridge, Tim D W ^b   Talbot, Kevin ^a   Sibson, Nicola R ^a   Turner, Martin R ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

biomarker; motor neuron disease; neurochemical; Nuclear magnetic resonance; proton

Indexed keywords

ALCOHOL; CITRIC ACID; GLUCOSE; LACTIC ACID; BIOLOGICAL MARKER;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CELL ENERGY; CELL METABOLISM; CEREBROSPINAL FLUID; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE DURATION; ENERGY METABOLISM; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; METABOLITE; METABOLOMICS; PREDICTIVE VALUE; PRIMARY LATERAL SCLEROSIS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; AGED; CASE CONTROL STUDY; DISCRIMINANT ANALYSIS; DISEASE COURSE; MIDDLE AGED; MULTIVARIATE ANALYSIS;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; BIOMARKERS; CASE-CONTROL STUDIES; CITRIC ACID; COHORT STUDIES; DISCRIMINANT ANALYSIS; DISEASE PROGRESSION; ETHANOL; FEMALE; GLUCOSE; HUMANS; LACTIC ACID; LONGITUDINAL STUDIES; MALE; METABOLOMICS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROTON MAGNETIC RESONANCE SPECTROSCOPY;

EID: 84947228229     PISSN: 21678421     EISSN: 21679223     Source Type: Journal    
DOI: 10.3109/21678421.2015.1053490     Document Type: Article

References (32)

1. Bowser R, Turner MR, Shefner J. Biomarkers in amyotrophic lateral sclerosis: opportunities and limitations. Nat Rev Neurol. 2011; 7: 631-8
2. Turner MR, Kiernan MC, Leigh PN, Talbot K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurology. 2009; 8: 94-109
3. Blasco H, Corcia P, Moreau C, Veau S, Fournier C, Vourch P, et al. 1H-NMR-based metabolomic profiling of CSF in early amyotrophic lateral sclerosis. PloS One. 2010; 5: e13223
4. Kumar A, Bala L, Kalita J, Misra UK, Singh RL, Khetrapal CL, et al. Metabolomic analysis of serum by (1) H NMR spectroscopy in amyotrophic lateral sclerosis. Clinica chimica acta; international journal of clinical chemistry. 2010; 411: 563-7
5. Lawton KA, Brown MV, Alexander D, Li Z, Wulff JE, Lawson R, et al. Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics. Amyotroph Lateral Scler Frontotemporal Degener. 2014; 15: 362-70
6. Rozen S, Cudkowicz ME, Bogdanov M, Matson WR, Kristal BS, Beecher C, et al. Metabolomic analysis and signatures in motor neuron disease. Metabolomics: Official journal of the Metabolomic Society. 2005; 1: 101-8
7. Blasco H, Corcia P, Pradat PF, Bocca C, Gordon PH, Veyrat-Durebex C, et al. Metabolomics in cerebrospinal fluid of patients with amyotrophic lateral sclerosis: an untargeted approach via high-resolution mass spectrometry. Journal of Proteome Research. 2013; 12: 3746-54
8. Lawton KA, Cudkowicz ME, Brown MV, Alexander D, Caffrey R, Wulff JE, et al. Biochemical alterations associated with ALS. Amyotrophic Lateral Sclerosis: official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases. 2012; 13: 110-8
9. Wuolikainen A, Andersen PM, Moritz T, Marklund SL, Antti H. ALS patients with mutations in the SOD1 gene have a unique metabolomic profile in the cerebrospinal fluid compared with ALS patients without mutations. Molecular Genetics and Metabolism. 2012; 105: 472-8
10. Wuolikainen A, Moritz T, Marklund SL, Antti H, Andersen PM. Disease related changes in the cerebrospinal fluid metabolome in amyotrophic lateral sclerosis detected by GC/TOFMS. PloS One. 2011; 6: e17947
11. Turner MR, Bowser R, Bruijn L, Dupuis L, Ludolph A, McGrath M, et al. Mechanisms, models and biomarkers in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013; 14 (Suppl 1): 19-32
12. Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron D. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis and other motor neuron disorders: official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. 2000; 1: 293-9
13. Waterman CL, Currie RA, Cottrell LA, Dow J, Wright J, Waterfield CJ, et al. An integrated functional genomic study of acute phenobarbital exposure in the rat. BMC Genomics. 2010; 11: 9
14. Skov T, van den Berg F, Tomasi G, Bro R. Automated alignment of chromatographic data. Journal of Chemometrics. 2006; 20: 484-97
15. Wishart DS, Jewison T, Guo AC, Wilson M, Knox C, Liu Y, et al. HMDB 3.0: The Human Metabolome Database in 2013. Nucleic acids research. 2013; 41 (Database issue):D801- 7
16. Wishart DS, Lewis MJ, Morrissey JA, Flegel MD, Jeroncic K, Xiong Y, et al. The human cerebrospinal fluid metabolome. Journal of chromatography B, Analytical technologies in the biomedical and life sciences. 2008; 871: 164-73
17. Blasco H, Nadal-Desbarats L, Pradat PF, Gordon PH, Antar C, Veyrat-Durebex C, et al. Untargeted 1H-NMR metabolomics in CSF: towards a diagnostic biomarker for motor neuron disease. Neurology. 2014; 82: 1167-74
18. Rothstein JD, Martin LJ, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med. 1992; 326: 1464-8
19. Bacman SR, Bradley WG, Moraes CT. Mitochondrial involvement in amyotrophic lateral sclerosis: trigger or target? Mol Neurobiol. 2006; 33: 113-31
20. Desport JC, Preux PM, Magy L, Boirie Y, Vallat JM, Beaufrere B, et al. Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis. Am J Clin Nutr. 2001; 74: 328-34
21. Funalot B, Desport JC, Sturtz F, Camu W, Couratier P. High metabolic level in patients with familial amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis: official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases. 2009; 10: 113-7
22. Dupuis L, Pradat PF, Ludolph AC, Loeffler JP. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurology. 2011; 10: 75-82
23. Desport JC, Torny F, Lacoste M, Preux PM, Couratier P. Hypermetabolism in ALS: correlations with clinical and paraclinical parameters. Neurodegenerative Diseases. 2005; 2: 202-7
24. Kasarskis EJ, Berryman S, Vanderleest JG, Schneider AR, McClain CJ. Nutritional status of patients with amyotrophic lateral sclerosis: relation to the proximity of death. The American Journal of Clinical Nutrition. 1996; 63: 130-7
25. de Jong SW, Huisman MH, Sutedja NA, van der Kooi AJ, de Visser M, Schelhaas HJ, et al. Smoking, alcohol consumption, and the risk of amyotrophic lateral sclerosis: a population based study. American Journal of Epidemiology. 2012; 176: 233-9
26. McManus IR, Contag AO, Olson RE. Characterization of Endogenous Ethanol in the Mammal. Science (New York, NY). 1960; 131: 102-3
27. Walker GW, Curry AS. Endogenous alcohol in body fluids. Nature. 1966; 210: 1368
28. Jones AW, Mardh G, Anggard E. Determination of endogenous ethanol in blood and breath by gas chromatography-mass spectrometry. Pharmacology, Biochemistry, and Behavior. 1983; 18 (Suppl 1): 267-72
29. Antoshechkin AG. On intracellular formation of ethanol and its possible role in energy metabolism. Alcohol and Alcoholism (Oxford, Oxfordshire). 2001; 36: 608
30. Meshitsuka S, Morio Y, Nagashima H, Teshima R. 1H-NMR studies of cerebrospinal fluid: endogenous ethanol in patients with cervical myelopathy. Clinica chimica acta; international journal of clinical chemistry. 2001; 312: 25-30
31. Mandal R, Guo AC, Chaudhary KK, Liu P, Yallou FS, Dong E, et al. Multi-platform characterization of the human cerebrospinal fluid metabolome: a comprehensive and quantitative update. Genome Med. 2012; 4: 38
32. Benatar M, Wuu J. Presymptomatic studies in ALS: rationale, challenges, and approach. Neurology. 2012; 79: 1732-9